Clinical trial
Phase I Study of MEDI522 in Patients With Irinotecan-Refractory Advanced…
NCT00284817 · MedImmune LLC, Industry · Completed
Key facts
| NCT number | NCT00284817 |
|---|---|
| Title | Phase I Study of MEDI522 in Patients With Irinotecan-Refractory Advanced Colorectal Cancer |
| Official title | Phase I Study of MEDI522, a Humanized Monoclonal Antibody Directed Against the Human Alpha V Beta 3 Integrin, in Patients With Irinotecan-Refractory Advanced Colorectal Cancer or Other Solid Tumors Refractory to Standard Therapy |
| Lead sponsor | MedImmune LLC, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Cancer |
| Intervention type | Drug |
| Interventions | MEDI-522 |
| Enrollment | 17 |
| Start date | Jul 1, 2001 |
| Primary completion | Jan 1, 2005 |
| Completion | May 1, 2005 |
| First posted | Feb 1, 2006 |
| Last update posted | May 29, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: